Navigation Links
Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine

GENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with migraine. The study achieved its primary objective, the absence of pain at 2 hours after dosing, with statistical significance, and also showed trends towards improvement in pain-free status and improvement of migraine pain at other time points. ADX10059 has already recently demonstrated a potential therapeutic benefit in a Phase IIa study in gastro-esophageal reflux disease (GERD), and is currently completing a Phase IIa study in anxiety.

ADX10059 is a potent, selective, negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5 NAM). Various pre-clinical pharmacology experiments have shown that glutamate is largely responsible for signal transmission in the neural circuit involved in migraine, and mGluR5 receptors are found at strategic points along the pathway. Inhibition of mGluR5 might therefore prevent the initiation of the migraine circuit, or interrupt it once established. For this initial exploratory study on the utility of an mGluR5 NAM in the management of migraine, an acute treatment paradigm was used.

The study was conducted in 129 migraine patients at opinion leader sites in the UK and Germany, according to the gold-standard design used for acute treatment of migraine. It comprised a multi-centre, double-blind, placebo-controlled comparison of a single dose of ADX10059 with placebo, to treat a single moderate or severe (IHS Grade 2 or 3) migraine headache, in an outpatient setting. Standard efficacy outcomes were used, with the primary efficacy variable being the proportion of patients pain-free (IHS Grade 0) 2 hours after dosing.

ADX10059 met the primary endpoint, showing a statistically significant higher number of patients pain-free 2 hours after dosing compared to placeb
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:3/2/2015)... , March 2, 2015 For the past 15 ... accidents per year in the U.S. alone (U.S. Census Bureau 2012). ... are minor fender benders BUT there are quite a few where ... cabin intrusion, which can obstruct the seatbelt release button or occupant ... being in any serious accidents in their lifetime but may still ...
(Date:3/2/2015)... Following announcements from both Novartis and ... Inc. (NASDAQ:  ARRY) today announced the completion of ... Novartis.  Along with global ownership of both assets, ... million from Novartis. Ron Squarer, Chief ... the Novartis-GSK transaction, Array now owns both binimetinib ...
(Date:3/2/2015)... , March 2, 2015 Leading patient ... kicking off the 2015 One Million Strong ... national campaign will raise awareness and funds for colorectal ... than one million colorectal cancer survivors living in ... disease with great strength and courage every day. ...
Breaking Medicine Technology:New SuperVizor, an Automobile Escape Tool, Ensures the Safety of Drivers and Passengers on the Road 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 3Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 4Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 5
... Tolerx, Inc. and GlaxoSmithKline (GSK) today ... an investigational humanized anti-CD3 monoclonal antibody, did not meet ... month 12 in patients with new-onset autoimmune type 1 ... data, no new or unexpected treatment-related safety concerns have ...
... MATEO, Calif., March 11, 2011 Sonitus Medical, Inc., ... non-surgical and removable hearing prosthetic to transmit sound via ... Mark certification for its SoundBite Hearing System. The company ... Assurance System Approval. This is the first European regulatory ...
Cached Medicine Technology:Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 2Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 3Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 4Sonitus Medical Receives European CE Mark for SoundBite™ Hearing System 2
(Date:3/2/2015)... 2015 Getting customers to discover a ... goal this March as the 31st annual Frozen Food ... National Frozen & Refrigerated Foods Association (NFRA) to stimulate ... more than 20 delicious frozen selections and is thrilled ... tasty frozen options are crafted with simple ingredients, no ...
(Date:3/2/2015)... Today at the State Capitol, Assemblymember ... the California Healthcare Institute (CHI) and the National ... resolution recognizing Feb. 28, 2015 as Rare Disease ... for millions of Californians living with nearly 7,000 ... research organization, representing leading California academic institutions, biotechnology, ...
(Date:3/2/2015)... Mirena IUD lawsuits ( http://www.mirenalawsuit2014.com/ ) ... by the long-acting birth control device continue to move ... according to Bernstein Liebhard LLP. In an Order ... on February 24th, the Court ruled that a Mirena ... pursue her lawsuit, which accuses Bayer Healthcare Pharmaceuticals of ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Dr. David ... injury, is partnering with Doctors on Liens ... patients. It’s rare for personal injury victims to ... and especially on a lien basis. However, San ... outstanding team of chiropractors, M.D., pain management physician, massage, ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Cutler Integrative ... get to the root, gives cutting-edge tips to bring ... way to renew the body by first cleaning house. ... Naturopathic medicine, “We are all Toxic.” Between environmental toxins ... of potential greatness, and our high stress levels, we ...
Breaking Medicine News(10 mins):Health News:Take a Fresh Look at Frozen with Ian’s 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 4Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2Health News:Skin and Wellness Power Couple give Quick Tips to Self-Renewal for Spring 2
... , THE WOODLANDS, Texas, Aug. 12 Medical oncologist and renowned cancer researcher ... has joined the US Oncolo g y Research ... of Nevada (CCCN), an affiliate of US Oncolog y ... Chair and Medical Director of the Developmental Therapeutics Committee for US Oncology Research and Co-Chair ...
... , , Milestone shows how ... how much the culture has changed when reporting medical events , ... Authority has collected over one million reports from Pennsylvania healthcare facilities since ... that did not cause harm to the patient. , , ...
... , , FALLS CHURCH, Va., ... CSC ) the top performer in enterprise resource planning (ERP) ... of vendor performance in healthcare technology. , , ... Staying on Target with ERP Implementations: A Report on Healthcare Consulting ...
... , GLEN BURNIE, Md., Aug. 12 ... of prescription medications and veterinary therapeutic diets, today announced ... Eli Lilly and Company. VetCentric,s prescription management service enables ... owners by utilizing VetCentric,s unique veterinary-supportive business model. , ...
... , , BASKING RIDGE, N.J., Aug. ... begin healthy habits. Verizon Wireless customers can access multiple applications that help ... , Applications , , ... GPS with maps, speed, distance, elevation, splits and calories. Save activities to ...
... , WASHINGTON, Aug. 12 Even though universal comprehensive ... more children being diagnosed and successfully treated for vision problems and ... three states require eye examinations for school-age children, according to a ... , The report, "Building a Comprehensive Child Vision ...
Cached Medicine News:Health News:Nicholas Vogelzang, MD, Joins US Oncology Research Network via Comprehensive Cancer Centers of Nevada 2Health News:Nicholas Vogelzang, MD, Joins US Oncology Research Network via Comprehensive Cancer Centers of Nevada 3Health News:Nicholas Vogelzang, MD, Joins US Oncology Research Network via Comprehensive Cancer Centers of Nevada 4Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 2Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 3Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 4Health News:Healthcare Providers Rank CSC First in ERP Implementations 2Health News:Healthcare Providers Rank CSC First in ERP Implementations 3Health News:VetCentric Partners with Elanco Animal Health 2Health News:Verizon Wireless Offers Healthy Applications to Turn a Mobile Phone Into a Personal Trainer 2Health News:New Evidence-Based Research Shows that Universal Comprehensive Eye Exams Would Help More Children Succeed in School 2Health News:New Evidence-Based Research Shows that Universal Comprehensive Eye Exams Would Help More Children Succeed in School 3Health News:New Evidence-Based Research Shows that Universal Comprehensive Eye Exams Would Help More Children Succeed in School 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: